Serum concentrations of adalimumab (ADA) may vary among equally dosed patients which can ultimately affect patient outcomes. Suboptimal levels of ADA have been lined to lower response rates in IBD patients. Furthermore, some patients may develop immunogenicity to ADA by producing antibodies to adalimumab (ATA). The presence of ATA has also been associated with increased rates of infusion reasctions and drug clearance leading to lower response rates. Therefore, the quantitative measurement of ADA and ATA levels in serum provides valuable information to help them gain a better understanding of the factors that may be affecting a patient's loss of response.
The Anser ADA test is a next generation quantitative monitoring assay that allows for measurement and mintoring serum ADA and ATA levels at anytime during therapy.